Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2012 1
2013 1
2014 2
2015 3
2016 3
2017 2
2018 1
2019 3
2020 6
2021 6
2022 2
2023 4
2024 3

Text availability

Article attribute

Article type

Publication date

Search Results

32 results

Results by year

Filters applied: . Clear all
Page 1
Advances in targets in inflammatory breast cancer.
Iwase T, Wang X, Thi Hanh Phi L, Sridhar N, Ueno NT, Lee J. Iwase T, et al. Int Rev Cell Mol Biol. 2024;384:125-152. doi: 10.1016/bs.ircmb.2023.10.005. Epub 2024 Feb 5. Int Rev Cell Mol Biol. 2024. PMID: 38637096 No abstract available.
Maintenance pembrolizumab therapy in patients with metastatic HER2-negative breast cancer with prior response to chemotherapy.
Iwase T, Cohen EN, Gao H, Alexander A, Kai M, Chiv V, Wang X, Krishnamurthy S, Liu D, Shen Y, Kida K, Reuben A, Layman R, Ramirez D, Tripathy D, Moulder SL, Yam C, Valero V, Lim B, Reuben JM, Ueno NT. Iwase T, et al. Clin Cancer Res. 2024 Apr 17. doi: 10.1158/1078-0432.CCR-23-2947. Online ahead of print. Clin Cancer Res. 2024. PMID: 38629963
Clinical outcomes after 1 versus 2-3 lines of neoadjuvant therapy in stage III inflammatory breast cancer.
Nakhlis F, Niman SM, Ueno NT, Troll E, Ryan S, Yeh E, Warren L, Bellon J, Harrison B, Iwase T, Carisa Le-Petross HT, Saleem S, Teshome M, Whitman GJ, Woodward WA, Overmoyer B, Tolaney SM, Regan M, Lynce F, Layman RM. Nakhlis F, et al. Among authors: iwase t. Breast Cancer Res Treat. 2024 Apr;204(2):289-297. doi: 10.1007/s10549-023-07195-5. Epub 2023 Dec 28. Breast Cancer Res Treat. 2024. PMID: 38155272
EGFR is a master switch between immunosuppressive and immunoactive tumor microenvironment in inflammatory breast cancer.
Wang X, Semba T, Manyam GC, Wang J, Shao S, Bertucci F, Finetti P, Krishnamurthy S, Phi LTH, Pearson T, Van Laere SJ, Burks JK, Cohen EN, Reuben JM, Yang F, Min H, Navin N, Trinh VN, Iwase T, Batra H, Shen Y, Zhang X, Tripathy D, Ueno NT. Wang X, et al. Among authors: iwase t. Sci Adv. 2022 Dec 16;8(50):eabn7983. doi: 10.1126/sciadv.abn7983. Epub 2022 Dec 16. Sci Adv. 2022. PMID: 36525493 Free PMC article.
32 results